T-Liven PR™: Market Leading
in T-Cell Potential
T-Liven PR impacts in vitro and in vivo T-Cell Performance in three critical ways*
Compared to cells grown in FBS or AB Serum, T-Cells expanded in T-Liven PR have been show to maintain a higher percentage of Central Memory and Naive phenotypes.
When used to treat murine solid and liquid tumor models, CAR-T cells grown in T-Liven PR were found to persist longer and were effective against a secondary tumor challenge.
In both a primary tumor model and in a re-challenge model, CAR T cells grown in T-Liven PR resulted in better tumor killing effect and survival.
* Torres Chavez, A., McKenna, M.K., Canestrari, E. et al. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. j. immunotherapy cancer7, 330 (2019). https://doi.org/10.1186/s40425-019-0804-9